Norinchukin Bank’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$15.2M Buy
120,669
+1,296
+1% +$171K 0.15% 91
2026
Q1
$16.6M Buy
119,373
+4,272
+4% +$598K 0.19% 77
2025
Q4
$14.1M Buy
115,101
+10,938
+11% +$1.33M 0.16% 92
2025
Q3
$11.6M Buy
104,163
+1,263
+1% +$144K 0.16% 98
2025
Q2
$11.4M Buy
102,900
+4,916
+5% +$523K 0.17% 93
2025
Q1
$11M Buy
97,984
+29,886
+44% +$3.08M 0.2% 81
2024
Q4
$6.29M Buy
68,098
+5,726
+9% +$516K 0.13% 104
2024
Q3
$5.23M Buy
62,372
+8,427
+16% +$643K 0.12% 109
2024
Q2
$3.7M Buy
53,945
+219
+0.4% +$14.6K 0.11% 118
2024
Q1
$3.94M Sell
53,726
-1,117
-2% -$85.9K 0.12% 117
2023
Q4
$4.44M Sell
54,843
-7,871
-13% -$613K 0.1% 98
2023
Q3
$4.7M Sell
62,714
-64,941
-51% -$5M 0.11% 99
2023
Q2
$9.84M Buy
127,655
+28,824
+29% +$2.3M 0.17% 97
2023
Q1
$8.2M Buy
98,831
+2,025
+2% +$168K 0.16% 91
2022
Q4
$8.31M Sell
96,806
-22,075
-19% -$1.75M 0.18% 84
2022
Q3
$7.33M Buy
118,881
+12,087
+11% +$762K 0.15% 103
2022
Q2
$6.6M Sell
106,794
-23,264
-18% -$1.44M 0.13% 108
2022
Q1
$7.73M Buy
130,058
+11,639
+10% +$744K 0.1% 121
2021
Q4
$8.6M Sell
118,419
-7,170
-6% -$494K 0.11% 112
2021
Q3
$8.77M Buy
125,589
+7,403
+6% +$520K 0.12% 110
2021
Q2
$8.14M Buy
118,186
+1,393
+1% +$93K 0.12% 107
2021
Q1
$7.55M Buy
116,793
+5,712
+5% +$368K 0.1% 109
2020
Q4
$6.47M Sell
111,081
-1,509
-1% -$91.1K 0.09% 110
2020
Q3
$7.12M Buy
112,590
+2,526
+2% +$175K 0.11% 97
2020
Q2
$8.47M Sell
110,064
-1,836
-2% -$141K 0.14% 86
2020
Q1
$8.37M Sell
111,900
-97,809
-47% -$6.76M 0.16% 79
2019
Q4
$13.6M Sell
209,709
-15,219
-7% -$991K 0.18% 90
2019
Q3
$14.3M Buy
224,928
+3,850
+2% +$252K 0.2% 86
2019
Q2
$14.9M Sell
221,078
-90,599
-29% -$5.96M 0.23% 70
2019
Q1
$20.3M Buy
311,677
+4,335
+1% +$288K 0.26% 73
2018
Q4
$19.2M Buy
307,342
+73,940
+32% +$5.17M 0.27% 71
2018
Q3
$18M Buy
233,402
+18,868
+9% +$1.42M 0.24% 73
2018
Q2
$15.2M Buy
214,534
+26,722
+14% +$1.89M 0.23% 79
2018
Q1
$14.2M Buy
187,812
+16,478
+10% +$1.31M 0.24% 75
2017
Q4
$12.3M Buy
171,334
+7,309
+4% +$555K 0.21% 80
2017
Q3
$13.3M Sell
164,025
-18,802
-10% -$1.44M 0.26% 66
2017
Q2
$12.9M Buy
182,827
+8,427
+5% +$561K 0.27% 61
2017
Q1
$11.8M Buy
174,400
+7,070
+4% +$497K 0.26% 61
2016
Q4
$12M Buy
167,330
+13,379
+9% +$994K 0.28% 58
2016
Q3
$12.2M Sell
153,951
-22,210
-13% -$1.8M 0.29% 58
2016
Q2
$14.7M Buy
176,161
+2,426
+1% +$215K 0.36% 45
2016
Q1
$16M Sell
173,735
-15,576
-8% -$1.4M 0.39% 41
2015
Q4
$19.2M Sell
189,311
-4,032
-2% -$420K 0.49% 34
2015
Q3
$19M Buy
193,343
+36,430
+23% +$4.05M 0.5% 33
2015
Q2
$18.4M Sell
156,913
-5,788
-4% -$632K 0.47% 36
2015
Q1
$16M Sell
162,701
-3,475
-2% -$353K 0.39% 37
2014
Q4
$15.7M Buy
166,176
+28,508
+21% +$2.95M 0.38% 39
2014
Q3
$14.7M Buy
137,668
+2,151
+2% +$211K 0.42% 32
2014
Q2
$11.2M Sell
135,517
-16,619
-11% -$1.29M 0.33% 42
2014
Q1
$10.8M Buy
152,136
+6,090
+4% +$478K 0.31% 46
2013
Q4
$11M Sell
146,046
-351
-0.2% -$24.4K 0.3% 45
2013
Q3
$9.2M Buy
146,397
+5,305
+4% +$317K 0.26% 47
2013
Q2
$7.23M Buy
+141,092
New +$7.35M 0.22% 49

Other funds holding GILD

Norinchukin Bank's GILD Position: Q2 2026 in Review

Norinchukin Bank increased its Gilead Sciences (GILD) stake by 1.1% in Q2 2026, buying an estimated $171K and bringing the position to 120,669 shares worth $15.2M. The position accounts for 0.15% of the portfolio, ranked #91.

Norinchukin Bank first reported a position in GILD in Q2 2013 and has held it in 53 quarters since. The position peaked at $20.3M in Q1 2019. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Norinchukin Bank held 120,669 shares of Gilead Sciences worth $15.2M as of Q2 2026.
  • Norinchukin Bank bought 1,296 Gilead Sciences shares in Q2 2026, an estimated $171K.
  • Gilead Sciences made up 0.15% of Norinchukin Bank's portfolio in Q2 2026, its #91 holding.
  • Norinchukin Bank first reported a position in Gilead Sciences in Q2 2013 and has held it in 53 quarters since.
  • Norinchukin Bank's Gilead Sciences position peaked at $20.3M in Q1 2019.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Norinchukin Bank's 13F filing for Q2 2026, filed 14 Aug 2026.